Ergothioneine for Cognitive Function

Verdict: Promising association, but causation unproven

Low blood ergothioneine is consistently linked to worse cognition and dementia, but the evidence that taking ergothioneine actually protects or improves cognition rests on a single 19-person pilot trial. It is too early to recommend it for brain health.

C 🟠 C Weak Evidence Published with Warning

🔬Why this grade7-layer evidence engine

The grade is C (weak evidence) because nearly all human data are observational, not interventional. A cross-sectional study of 496 people found dementia patients had the lowest plasma ergothioneine (p<0.001), tracking with hippocampal atrophy, cortical thinning and white-matter lesions (PMID 34673145). A Singapore cohort showed whole-blood levels fall after age 60, with mild-cognitive-impairment elders measuring significantly lower than cognitively normal peers (PMID 27444382). Two reviews echo that lower levels accompany faster cognitive decline (PMID 35090053; PMID 38018890).

The catch is that association is not causation. These designs cannot rule out reverse causation, dementia or its dietary changes may lower ergothioneine, or confounding, where low levels simply mark poor diet (few mushrooms) or worse general health. The only interventional data come from a tiny double-blind pilot RCT in 19 MCI adults taking 25 mg three times weekly for a year, which hinted at better learning and stable neurofilament light, but n=19 is far too small to prove benefit (PMID 39544014).

Authorities reinforce the caution. The FDA recognizes synthetic L-ergothioneine only as GRAS for food safety, with no approved cognitive or disease claim, and EFSA's 2016 opinion likewise addressed only novel-food safety. NHS, WHO, NIH ODS and major clinics (Mayo, Cleveland, Harvard) do not address it for cognition. It appears safe, but its clinical cognitive benefit is unestablished.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.57
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Published with Warning
Confidence
67%
Broadly consistent
Evidence level
E7
Single small RCT

How strongly each layer supports this effect

lower = less supportive
L1 ExamineGlobal benchmark
0.50
L3 MechanismPlausibility
0.50
L5 Clinical bodiesAuthoritative stance
0.50
L11 AI re-checkIndependent read
0.50
L2 PubMedPrimary literature
0.75
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.575
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 無高階證據可裁決
  4. tier_strict_requirement_check — B 級條件未達 (需 E1-E6;實際 E7)
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (5)L2 · primary research & systematic reviews

Investigating the efficacy of ergothioneine to delay cognitive decline in mild cognitively impaired subjects: A pilot study
PMID: 39544014 2024 RCT (double-blind) n = 19
Finding: 鋸定為先導試驗(n=19,MCI,≥60 歲):麥角硫因組學習能力評估表現改善,且血漿神經絲輕鏈(NfL,神經損傷標記)維持穩定;安慰劑組無認知改善且 NfL 顯著上升。屬樣本極小之探索性陽性訊號,需大型試驗確認。
🟠 Limited quality Academic Effect size: 小樣本探索性;學習能力改善 + NfL 穩定(組間方向有利但 n=19,未足以定論)
View on PubMed
Low plasma ergothioneine levels are associated with neurodegeneration and cerebrovascular disease in dementia
PMID: 34673145 2021 Cross-sectional n = 496
Finding: n=496(88 無認知障礙、201 認知障礙無失智 CIND、207 失智):失智組血漿麥角硫因濃度最低(p<0.001 vs NCI 與 CIND);低麥角硫因與白質高訊號、皮質厚度下降、海馬體積縮小相關。屬橫斷面關聯,無法證明因果。
Academic Effect size: 失智組 ET 最低(p<0.001);ET 與神經退化影像標記負相關
View on PubMed
Ergothioneine levels in an elderly population decrease with age and incidence of cognitive decline; a risk factor for neurodegeneration?
PMID: 27444382 2016 Cohort
Finding: 新加坡老年族群:全血麥角硫因濃度於 60 歲後顯著下降;輕度認知障礙(MCI)老年人之血漿麥角硫因顯著低於認知正常之同齡對照。提出低麥角硫因可能為神經退化之風險因子(標題即以問句呈現,作者自陳為假設)。屬觀察性關聯。
Academic Effect size: MCI 組 ET 顯著低於對照(觀察性關聯)
View on PubMed
Decline of ergothioneine in frailty and cognition impairment
PMID: 35090053 2022 Review
Finding: 回顧:阿茲海默症失智患者麥角硫因濃度下降與認知功能惡化、海馬萎縮相關;S-methyl-ergothioneine 等相關代謝物亦下降,而 indoxyl-sulfate、quinolinic acid 等有害代謝物上升。定位麥角硫因為認知障礙之潛在生物標記。屬代謝體學關聯之回顧整理。
Academic Effect size: N/A(回顧)
View on PubMed
Ergothioneine: an underrecognised dietary micronutrient required for healthy ageing?
PMID: 38018890 2023 Review
Finding: 回顧(Br J Nutr):明文『較低的麥角硫因濃度與較快速的認知退化相關』,並指血中濃度於 60 歲後下降;提出麥角硫因或應視為『條件性必需』微量營養素。為關聯性與假設之整理,非介入證據。
Academic Effect size: N/A(回顧;引用觀察性關聯)
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
FDA GRAS Notice Inventory portal (search-only); direct WebFetch of inventory returned HTTP 404 — substance-level GRN entry not retrievable verbatim source↗
L4b EU EFSA
Neutral
Safety of synthetic L-ergothioneine (Ergoneine) as a novel food (EFSA NDA Panel Scientific Opinion, DOI 10.2903/j.efsa.2016.4629) source↗
L4d TW TFDA / 衛福部
Cautious
麥角硫因(Ergothioneine)為菇蕈類等天然食材中所含之含硫胺基酸成分 source↗
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬5 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-cognitive-function-INT-ergothioneine-001 繁體中文版 →